RADNOR, Pa., Nov. 15, 2016 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") on behalf of purchasers of the Company's securities between July 3, 2014 and September 9, 2016, inclusive (the "Class Period"). Investors who purchased Taro securities during the Class Period may, no later than December 26, 2016, petition the Court to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action please visit https://www.ktmc.com/new-cases/taro-pharmaceutical-industries-ltd#join. Taro shareholders who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP ( Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299 - 7706 or at firstname.lastname@example.org. Taro is a pharmaceutical company that offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The shareholder class action complaint alleges that, during the Class Period, Taro and certain of its executive officers made false and/or misleading statements and/or failed to disclose that: (1) since 2014, Taro has colluded with other pharmaceutical companies to keep the price of generic products artificially high; (2) the foregoing conduct violated federal antitrust laws; (3) in turn, Taro's revenues during the Class Period were the result of illegal conduct; and (4) as a result, Taro's public statements were materially false and misleading at all relevant times.